Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | BRD3 | Q15059 | 9/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21132803 | 0.94 | PDE4D (0.53) | PDE4DTP53SMN1; SMN2MAPTRXFP1 | |
| SCHEMBL19079719 | 0.92 | PDE4D (0.55) | PDE4DTP53SMN1; SMN2MAPTRXFP1 | |
| SCHEMBL19090701 | 0.89 | PDE4D (0.52) | PDE4DTP53SMN1; SMN2MAPTRXFP1 | |
| SCHEMBL19090344 | 0.87 | PDE4D (0.56) | PDE4DTP53SMN1; SMN2MAPTRXFP1 | |
| SCHEMBL21132578 | 0.85 | PDE4D (0.64) | PDE4DTP53SMN1; SMN2MAPTRXFP1 | |
| SCHEMBL21132802 | 0.84 | PDE4D (0.61) | PDE4DTP53SMN1; SMN2MAPTRXFP1 | |
| SCHEMBL19090343 | 0.82 | PDE4D (0.43) | PDE4DTP53SMN1; SMN2MAPTBRD3 | |
| SCHEMBL19079744 | 0.82 | PDE4D (0.55) | PDE4DTP53SMN1; SMN2MAPTRXFP1 | |
| SCHEMBL19079890 | 0.80 | PDE4D (0.55) | PDE4DTP53SMN1; SMN2MAPTRXFP1 | |
| SCHEMBL21132579 | 0.80 | PDE4D (0.64) | PDE4DTP53SMN1; SMN2MAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329304-B2 | Compounds and methods for inhibition of hedgehog signaling and phosphodiesterase | VANDERBILT UNIVERSITY (US) | 2019-06-25 | — | — | US | disclosed |
| US-20170190717-A1 | Compounds and Methods for Inhibition of Hedgehog Signaling and Phosphodiesterase | VANDERBILT UNIVERSITY | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329304-B2 | Compounds and methods for inhibition of hedgehog signaling and phosphodiesterase | PDE4A, PDE4B, PDE7A | PDE4D 6/4885TP53 4300/4885SMN1; SMN2 4025/4885 |
| US-20170190717-A1 | Compounds and Methods for Inhibition of Hedgehog Signaling and Phosphodiesterase | PDE4A, PDE4B, PDE7A | PDE4D 6/4885TP53 4300/4885SMN1; SMN2 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.